GB1599133A - Biological reagents and their use - Google Patents
Biological reagents and their use Download PDFInfo
- Publication number
- GB1599133A GB1599133A GB1592/78A GB159278A GB1599133A GB 1599133 A GB1599133 A GB 1599133A GB 1592/78 A GB1592/78 A GB 1592/78A GB 159278 A GB159278 A GB 159278A GB 1599133 A GB1599133 A GB 1599133A
- Authority
- GB
- United Kingdom
- Prior art keywords
- dopamine receptor
- radioactive
- binder
- haloperidol
- test kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003153 chemical reaction reagent Substances 0.000 title description 3
- 102000015554 Dopamine receptor Human genes 0.000 claims abstract description 92
- 108050004812 Dopamine receptor Proteins 0.000 claims abstract description 92
- 239000003176 neuroleptic agent Substances 0.000 claims abstract description 55
- 239000011230 binding agent Substances 0.000 claims abstract description 44
- 230000002285 radioactive effect Effects 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 42
- 210000001124 body fluid Anatomy 0.000 claims abstract description 40
- 239000010839 body fluid Substances 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 40
- 210000002966 serum Anatomy 0.000 claims abstract description 32
- 210000002381 plasma Anatomy 0.000 claims abstract description 26
- 241000282414 Homo sapiens Species 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 230000027455 binding Effects 0.000 claims abstract description 20
- 230000005764 inhibitory process Effects 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 55
- 229960003878 haloperidol Drugs 0.000 claims description 45
- 238000003556 assay Methods 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 32
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 23
- 229950001675 spiperone Drugs 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 15
- 229960003638 dopamine Drugs 0.000 claims description 11
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 9
- 229960003634 pimozide Drugs 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 claims description 9
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 8
- 229960002507 benperidol Drugs 0.000 claims description 8
- 229960002784 thioridazine Drugs 0.000 claims description 8
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 claims description 7
- 244000309466 calf Species 0.000 claims description 7
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 7
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 7
- 229960001184 clopenthixol Drugs 0.000 claims description 7
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 7
- 229960004170 clozapine Drugs 0.000 claims description 7
- 229960002419 flupentixol Drugs 0.000 claims description 7
- 229960003532 fluspirilene Drugs 0.000 claims description 7
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims description 7
- 229960000423 loxapine Drugs 0.000 claims description 7
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 7
- 229960002324 trifluoperazine Drugs 0.000 claims description 7
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims description 7
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 210000001159 caudate nucleus Anatomy 0.000 claims description 6
- 229960001076 chlorpromazine Drugs 0.000 claims description 6
- 229910052722 tritium Inorganic materials 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 claims description 4
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 4
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 4
- 229960004046 apomorphine Drugs 0.000 claims description 4
- 229960002690 fluphenazine Drugs 0.000 claims description 4
- 210000005171 mammalian brain Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- -1 chorpromazine Chemical compound 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 239000012086 standard solution Substances 0.000 claims description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 3
- 229960000762 perphenazine Drugs 0.000 claims 3
- 230000000701 neuroleptic effect Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 description 41
- 229940079593 drug Drugs 0.000 description 40
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 239000000872 buffer Substances 0.000 description 15
- 239000003446 ligand Substances 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 11
- 229960005070 ascorbic acid Drugs 0.000 description 10
- 235000010323 ascorbic acid Nutrition 0.000 description 10
- 239000011668 ascorbic acid Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- 102000005915 GABA Receptors Human genes 0.000 description 5
- 108010005551 GABA Receptors Proteins 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000010807 negative regulation of binding Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960001779 pargyline Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UCTMLZBVNPSJHC-UHFFFAOYSA-N 5-(2-aminoethyl)cyclohexa-2,4-diene-1,2-diol Chemical compound NCCC1=CC=C(O)C(O)C1 UCTMLZBVNPSJHC-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003684 drug solvent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000002222 superior cervical ganglion Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9413—Dopamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75998577A | 1977-01-17 | 1977-01-17 | |
| US82853777A | 1977-08-29 | 1977-08-29 | |
| US05/845,554 US4197288A (en) | 1977-01-17 | 1977-10-26 | Neuroleptic radioreceptor assay method and kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1599133A true GB1599133A (en) | 1981-09-30 |
Family
ID=27419530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1592/78A Expired GB1599133A (en) | 1977-01-17 | 1978-01-16 | Biological reagents and their use |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS53112795A (enrdf_load_stackoverflow) |
| CH (1) | CH644456A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2801679A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2377634A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1599133A (enrdf_load_stackoverflow) |
| NL (1) | NL7800517A (enrdf_load_stackoverflow) |
| SE (1) | SE448189B (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4248853A (en) * | 1978-09-08 | 1981-02-03 | Solomon Halbert Snyder | Assay method and kit |
-
1978
- 1978-01-16 SE SE7800462A patent/SE448189B/sv not_active IP Right Cessation
- 1978-01-16 GB GB1592/78A patent/GB1599133A/en not_active Expired
- 1978-01-16 CH CH41778A patent/CH644456A5/de not_active IP Right Cessation
- 1978-01-16 NL NL7800517A patent/NL7800517A/xx not_active Application Discontinuation
- 1978-01-16 FR FR7801052A patent/FR2377634A1/fr active Granted
- 1978-01-16 DE DE19782801679 patent/DE2801679A1/de not_active Withdrawn
- 1978-01-17 JP JP365278A patent/JPS53112795A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR2377634A1 (fr) | 1978-08-11 |
| JPS53112795A (en) | 1978-10-02 |
| SE7800462L (sv) | 1978-07-18 |
| FR2377634B1 (enrdf_load_stackoverflow) | 1983-04-29 |
| DE2801679A1 (de) | 1978-07-20 |
| SE448189B (sv) | 1987-01-26 |
| NL7800517A (nl) | 1978-07-19 |
| CH644456A5 (en) | 1984-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scheffel et al. | Labeling of human platelets with [111In] 8-hydroxyquinoline | |
| Rehfeld et al. | Immunoreactive gastrin components in human serum | |
| US4197288A (en) | Neuroleptic radioreceptor assay method and kit | |
| Adkinson Jr et al. | Cross-allergenicity and immunogenicity of aztreonam | |
| Irvine | The immunoassay of gastric intrinsic factor and the titration of antibody to intrinsic factor | |
| Conaway et al. | Double-antibody radioimmunoassay for parathyroid hormone | |
| Worwood et al. | The clearance of 131I-human plasma ferritin in man | |
| SK12172001A3 (sk) | Súprava na rádioizotopové značenie proteínov ytriom-90 | |
| US4520112A (en) | Assay method for organic calcium antagonist drugs and a kit for such an assay | |
| MORI et al. | Studies of an in vitro binding reaction between thyroid microsomes and long acting thyroid stimulator globulin (LATS): I. Development of solid-state competitive binding radioassay methods for measurement of antimicrosomal and antithyroglobulin antibodies | |
| Velcovsky et al. | Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA) | |
| Vierling et al. | Incorporation of radiocopper into ceruloplasmin in normal subjects and in patients with primary biliary cirrhosis and Wilson's disease | |
| Cragg et al. | Turnover of 131I‐human spleen ferritin in plasma | |
| McAdams et al. | Comparison of antigenic sources for acetylcholine receptor antibody assays in myasthenia gravis | |
| GB1599133A (en) | Biological reagents and their use | |
| Lader | A radioreceptor assay for neuroleptic drugs in plasma | |
| US4299813A (en) | Assay kit and method | |
| CA1126632A (en) | Assay method and kit | |
| US3929981A (en) | Method for determining thyroid function | |
| Hall et al. | Binding of [3H] SCH 39166 to human post mortem brain tissue | |
| Habener et al. | Improved radioimmunoassay for calcitonin using 125I-labelled calcitonin purified by gel filtration | |
| US4248853A (en) | Assay method and kit | |
| Cope et al. | Simplification of urinary aldosterone measurement by radioimmunoassay | |
| Rhodes et al. | The use of Limulus testing to reduce the incidence of adverse reactions to cisternographic agents | |
| Neurath | [7] Use of 125I-labeled anti-2, 4-dinitrophenyl (DNP) antibodies as a general tracer in solid-phase radioimmunoassays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |